Frank Diamond
Senior Editor
MANAGED CARE May 2002. ©MediMedia USA

The government offers financial incentives that include $100,000 in seed money, risk-sharing deals, and higher payment rates.

Senior Editor

The federal government wants to make it easier for PPOs to participate in Medicare+Choice, but health insurers must hurry if they'd like to take part in demonstration projects slated to get under way next Jan. 1.

The Centers for Medicare and Medicaid Services published a notice calling for PPO participation in M+C in the Federal Register on April 15 that includes offers of $100,000 in seed money as well as waivers from the program's payment guidelines. The agency wants to use a competitive application process to serve beneficiaries better.

"Our objective is to introduce more variety into the Medicare+Choice program so that Medicare beneficiaries have broader choice and more options available," the notice says. Currently, of the 179 M+C contracts, only two are PPOs.

Applications must be filed by May 30.

"We haven't gotten any feedback from our members to suggest that the time frames will present a barrier," says Susan Pisano, a spokeswoman for the American Association of Health Plans. "However, it is a more realistic opportunity for a company that already has a PPO network in place."

"It is rushing things," admits Alissa Fox, director of policy at the Blue Cross/Blue Shield Association, "but they have a great objective. Their objective is to have it up and running Jan. 1. We're happy about that. It's quick, but we've done a lot of thinking about this."

CMS aims to have the options available to beneficiaries by autumn's open-enrollment period. The PPO push is slated to take place in 12 geographic areas (yet to be chosen) and is intended to last three years. CMS has not placed a limit on how many plans may participate.

"For each selected demonstration, we will assign a project officer who will serve as the point of contact with the demonstration project staff and who will provide technical consultation regarding waiver requirements, implementation, and monitoring activities, and also provide feedback to us on demonstration status," the notice says.

Despite looking minuscule relative to the kind of money usually discussed in managed care, the $100,000 being offered to help launch the PPOs came as a nice surprise, says Fox.

"A lot of these demonstration projects don't pay for start-up costs," she says. "We're real pleased that they've put that in there. It's probably not enough, but it's great that they put some amount of money in there."

Welcomed waivers

Participating PPOs will not all have the same level of flexibility, but some of the things that health insurers can get are:

  • Payment based on the higher of either M+C or fee-for-service rates;
  • Risk-sharing arrangements with CMS (see "PPOs Must Show What's at Stake");
  • Not having to submit "adjusted community rate" proposals; and
  • Scaled-back requirements regarding the size and composition of physician networks.

CMS makes it clear that it will try hard to reward participation. For example, the agency states that while "we cannot waive quality assurance requirements, our payment-related waiver authority could potentially have the effect of permitting an entity to operate a PPO product under this demonstration without being subject to quality assurance requirements that would otherwise apply."

CMS has held numerous meetings with industry representatives to find out what needs to be done to encourage PPO participation.

"We've identified a number of things that could be changed in order to have PPOs work in Medicare," says Fox. A Blue Cross/Blue Shield white paper on the subject was one of the documents on which CMS based its Federal Register notice.

Despite such industry input, however, health insurers still seem somewhat reluctant to make a commitment.

"We're studying the proposal and everything that CMS is offering or proposing for introducing a PPO product," says Mary Sellers, a Humana spokeswoman. "We're pretty much supportive of providing benefits with the types of options to our Medicare+Choice members as would be available to those who are under 65, but beyond that, I think we're really still evaluating — and it would be premature for us to say more than that."

That seems to be the stance taken by many health plans.

"I don't really have a way to gauge the level of interest right now," says the AAHP's Pisano. "What I can tell you is that this community has always been highly supportive of there being available to beneficiaries the kinds of choices that are available to people with employer-sponsored coverage."

It will cost more

Of course, one of those choices CMS would like to see offered is prescription drug coverage, but that — like other benefits beyond what's presented in fee-for-service Medicare — will cost more.

"Choice always comes at a price," notes Thomas Morrow, MD, the medical director at One Health Plan of Georgia. "Most of the PPOs come with a 20-percent copayment. With the HMOs, the full freight's paid. The entire bill is paid by the HMO except for, typically, a small copayment."

Still, there seems to be support for the PPO option, because it mirrors what's taking place in managed care overall, says Morrow.

"We're seeing that the PPOs are growing faster than the HMOs," he notes. "PPOs are where the commercial population is growing, because of the choices they offer."

It remains to be seen how much Medicare beneficiaries will value such choices.

For more information: Health plan executives seeking more data about PPO demonstration projects may contact Ron Deacon, a CMS project officer, at (410) 786-6622 or

PPOs must show what's at stake

The Centers for Medicare and Medicaid Services says that any insurer that wants to work out a risk-sharing arrangement with the government for a Medicare+Choice PPO needs to describe its proposal in detail. "The applicant should include examples that illustrate the risk-sharing arrangement," the CMS notice in the Federal Register says. "The shared risk of gain or loss between CMS and the PPO must be symmetrical, and the PPO will always remain at significant financial risk."

In a white paper it submitted to CMS, the Blue Cross/Blue Shield Association outlined one possible risk-sharing arrangement based on a prospective target that would be equal to total premium minus administrative charges.

Computing medical expense target
CMS monthly M+C payment $500
Beneficiary premium $50
Total premium $550
Negotiated administrative charges ($40)
Medical expense target $510
What's gained, what's lost under 50/50 shared-risk agreement
  Gain scenario Loss scenario
Medical expense target $510 $510
Actual medical expenses $480 $530
Plan savings $15  
CMS savings $15  
Plan loss   $10
CMS loss   $10


Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.